{"status": "ok", "totalResults": 44, "articles": [{"source": {"id": null, "name": "Fool.com"}, "author": "newsfeedback@fool.com (Keith Speights)", "title": "3 Top Big Pharma Stocks to Buy Now", "description": "Great dividends and great growth prospects make these big pharma stocks great picks for long-term investors.", "url": "https://www.fool.com/investing/2018/09/06/3-top-big-pharma-stocks-to-buy-now.aspx", "urlToImage": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F493451%2Fpharmaceutical-research.jpg&h=630&w=1200&op=resize", "publishedAt": "2018-09-06T10:30:00Z", "content": "Some people stick the word \"big\" in front of an industry name in an effort to disparage the largest players in that particular market. When I use the term \"big pharma,\" though, I'm not intending to be derogatory. My use of the label is to simply refer to the \u2026 [+4543 chars]"}, {"source": {"id": null, "name": "Yahoo.com"}, "author": null, "title": "Pfizer's Skin Disease Drug Gets Breakthrough Therapy Status", "description": "Pfizer's (PFE) investigational oral JAK3 inhibitor PF-06651600 gets Breakthrough Therapy designation from the FDA for alopecia areata.", "url": "https://finance.yahoo.com/news/pfizer-apos-skin-disease-drug-145702447.html", "urlToImage": "https://s.yimg.com/uu/api/res/1.2/RcSGEOiRo4N.qL406x4Pog--~B/dz0wO3NtPTE7YXBwaWQ9eXRhY2h5b24-/http://media.zenfs.com/en-US/homerun/zacks.com/df5ad064f24e5502d8d1fb68bd8dc90d", "publishedAt": "2018-09-06T14:57:02Z", "content": "Pfizer, Inc. PFE announced that it has received Breakthrough Therapy designation for its pipeline candidate, PF-06651600 from the FDA. The candidate is being developed for alopecia areata, a chronic autoimmune skin disease that causes hair loss on the scalp, \u2026 [+3625 chars]"}, {"source": {"id": null, "name": "Yahoo.com"}, "author": null, "title": "3 Top Big Pharma Stocks to Buy Now", "description": "Great dividends and great growth prospects make these big pharma stocks great picks for long-term investors.", "url": "https://finance.yahoo.com/news/3-top-big-pharma-stocks-103000865.html", "urlToImage": "https://s.yimg.com/uu/api/res/1.2/dMhJrTHQFTunhg6UyrJWsA--~B/aD0zODc7dz01ODA7c209MTthcHBpZD15dGFjaHlvbg--/http://media.zenfs.com/en-US/homerun/motleyfool.com/cac2a8c273ac939ed15d71ebb32efe02", "publishedAt": "2018-09-06T10:30:00Z", "content": "Some people stick the word \"big\" in front of an industry name in an effort to disparage the largest players in that particular market. When I use the term \"big pharma,\" though, I'm not intending to be derogatory. My use of the label is to simply refer to the \u2026 [+4838 chars]"}, {"source": {"id": null, "name": "Fool.com"}, "author": "newsfeedback@fool.com (Cory Renauer)", "title": "Sangamo's Zinc Fingers Fail Again. Time to Walk Away?", "description": "Here's what investors need to know about the disappointing results Sangamo announced recently.", "url": "https://www.fool.com/investing/2018/09/06/sangamos-zinc-fingers-fail-again-time-to-walk-away.aspx", "urlToImage": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F493528%2Fbusinessman-in-shock-hands-on-head-laptop-surprise-investment-getty.jpg&h=630&w=1200&op=resize", "publishedAt": "2018-09-06T12:48:00Z", "content": "An attempt to edit genetic flaws on the fly didn't work nearly as well as hoped for Sangamo Therapeutics, Inc. ( NASDAQ:SGMO ), and the stock just took a dip. Is it time to cut and run? Before investors do any panic trading, there are a few things they need t\u2026 [+4435 chars]"}, {"source": {"id": null, "name": "Fool.com"}, "author": "newsfeedback@fool.com (Keith Speights)", "title": "Why Sangamo Therapeutics, Inc. Sank Again Today", "description": "Disappointing interim results for its gene-editing therapy continued to weigh on the biotech stock.", "url": "https://www.fool.com/investing/2018/09/06/why-sangamo-therapeutics-inc-sank-again-today.aspx", "urlToImage": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F493757%2Fdoctor-with-dna-and-question-mark.jpg&h=630&w=1200&op=resize", "publishedAt": "2018-09-06T21:00:00Z", "content": "What happened Shares of Sangamo Therapeutics, Inc. ( NASDAQ:SGMO ) were down 10.5% as of 3:34 p.m. EDT on Thursday. This marked the second consecutive day of double-digit percentage declines following the biotech's interim update from a phase 1/2 clinical stu\u2026 [+2158 chars]"}, {"source": {"id": null, "name": "Fiercebiotech.com"}, "author": "Phil Taylor", "title": "Allogene raises another $120M for off-the-shelf CAR-T programs", "description": "Allogene\u2019s bustling first few months has continued with a $120 million private financing round that will help it advance its off-the-shelf CAR-T therapies for cancer.", "url": "https://www.fiercebiotech.com/biotech/allogene-raises-120m-more-for-off-shelf-car-t-programs?utm_source=internal&utm_medium=rss", "urlToImage": "https://qtxasset.com/fiercebiotech/1536237546/gold_piggy_bank.jpg/gold_piggy_bank.jpg?fAca5m0txEEIn7c85yHItb9bxKQSJq2F", "publishedAt": "2018-09-06T12:40:15Z", "content": "Allogene\u2019s bustling first few months has continued with a $120 million private financing round that will help it advance its off-the-shelf CAR-T therapies for cancer. The biotech\u2014formed by Kite Pharma executives Arie Belldegrun and David Chang\u2014came out of ste\u2026 [+2415 chars]"}, {"source": {"id": null, "name": "Forbes.com"}, "author": "Arlene Weintraub, Contributor, Arlene Weintraub, Contributor https://www.forbes.com/sites/arleneweintraub/", "title": "Will Trump's Pharma Shaming Bring Down Drug Prices? Not Likely, Poll Says", "description": "President Trump promised \u201cvoluntary massive drops in prices\u201d from Big Pharma. Americans are skeptical.", "url": "https://www.forbes.com/sites/arleneweintraub/2018/09/06/will-trumps-pharma-shaming-bring-down-drug-prices-not-likely-poll-says/", "urlToImage": "https://thumbor.forbes.com/thumbor/600x315/https%3A%2F%2Fspecials-images.forbesimg.com%2Fdam%2Fimageserve%2F813697758%2F960x0.jpg%3Ffit%3Dscale", "publishedAt": "2018-09-06T13:24:00Z", "content": "Share to facebook Share to twitter Share to linkedin High drug costs are a concern for voters in the 2018 midterm elections, a new poll reveals. (Source: Getty Royalty Free) In July, Pfizer put plans to raise the prices of some of its products on hold after P\u2026 [+6873 chars]"}, {"source": {"id": null, "name": "Forbes.com"}, "author": "Joshua Cohen, Contributor, Joshua Cohen, Contributor https://www.forbes.com/sites/joshuacohen/", "title": "Tanezumab's Phase 3 Results: A Promising Sign For Non-Opioid Pain Treatments", "description": "As the opioid crisis has unfolded concerns have grown about dependency and the potentially addictive nature of opioid-based pain treatments. Having satisfactory non-opioid treatment alternatives will need to be an integral part of effective pain management.", "url": "https://www.forbes.com/sites/joshuacohen/2018/09/06/tanezumabs-phase-3-results-a-promising-sign-for-non-opioid-pain-treatments/", "urlToImage": "https://thumbor.forbes.com/thumbor/600x315/https%3A%2F%2Fspecials-images.forbesimg.com%2Fdam%2Fimageserve%2F8850fc86753847019b09c48891d47021%2F960x0.jpg%3Ffit%3Dscale", "publishedAt": "2018-09-06T12:11:00Z", "content": "Share to facebook Share to twitter Share to linkedin This Wednesday, March 29, 2017 photo shows a syringe involved in an experimental non-opioid pain medication trial at the Altoona Center for Clinical Research in Altoona, Pa. With about 2 million Americans a\u2026 [+11353 chars]"}, {"source": {"id": "the-hindu", "name": "The Hindu"}, "author": "Special Correspondent", "title": "Indices gain after six days of decline", "description": "Even as the rupee touched a new low on Thursday by falling below the 72-mark against the U.S. dollar for the first time ever, the benchmark equity ind", "url": "https://www.thehindu.com/business/indices-gain-after-six-days-of-decline/article24885253.ece", "urlToImage": "https://www.thehindu.com/static/theme/default/base/img/og-image.jpg", "publishedAt": "2018-09-06T16:45:45Z", "content": "Even as the rupee touched a new low on Thursday by falling below the 72-mark against the U.S. dollar for the first time ever, the benchmark equity indices gained ground after six consecutive days of losses. The 30-share Sensex gained 224.50 points, or 0.59%, \u2026 [+1405 chars]"}, {"source": {"id": null, "name": "Fiercepharma.com"}, "author": "Eric Palmer", "title": "Hospital-backed Civica Rx nabs Amgen vet as CEO and targets 14 drugs to knock off", "description": "A group of hospitals committed to manufacturing their own drugs to battle shortages and high costs now has a name, more support and a pharma manufacturing veteran to oversee the effort.", "url": "https://www.fiercepharma.com/manufacturing/hospital-supported-civica-rx-to-produce-14-drugs-are-chronic-shortage?utm_source=internal&utm_medium=rss", "urlToImage": "https://qtxasset.com/fiercepharma/1536241650/GettyImages-895696384.jpg/GettyImages-895696384.jpg?_0g8qRZNNplS44iztfBh49aN86_nts4W", "publishedAt": "2018-09-06T13:44:35Z", "content": "A group of hospitals committed to manufacturing their own drugs to battle shortages and high costs now has a name, more support and a pharma manufacturing veteran to oversee the effort. First announced in January as Project Rx, today the group said it will be\u2026 [+3149 chars]"}, {"source": {"id": null, "name": "Channelnewsasia.com"}, "author": null, "title": "Lilly's Elanco unit expects IPO to raise up to US$1.45 billion", "description": "Eli Lilly & Co's Elanco Animal Health unit on Thursday said it expects its initial public offering of 62.9 million shares to raise up to US$1.45 billion.", "url": "https://www.channelnewsasia.com/news/business/lilly-s-elanco-unit-expects-ipo-to-raise-up-to-us-1-45--billion-10690970", "urlToImage": "http://www.channelnewsasia.com/blob/10690968/55dc088d92d39a634c65f42c3c2e2c15/eli-lilly--amp--co-ceo-dave-ricks-poses-for-a-picture-at-the-j-p--morgan-healthcare-conference-in-san-francisco-1-data.jpg", "publishedAt": "2018-09-06T11:40:29Z", "content": "REUTERS: Eli Lilly &amp; Co's Elanco Animal Health unit on Thursday said it expects its initial public offering of 62.9 million shares to raise up to US$1.45 billion. The IPO is expected to be priced between US$20-US$23 per share. At the high end of the range\u2026 [+730 chars]"}, {"source": {"id": null, "name": "Yahoo.com"}, "author": null, "title": "Credit Suisse Joins Consensus To Prescribe Sarepta", "description": "The Street has a lot of faith in Sarepta Therapeutics, Inc. (NASDAQ: SRPT ). The biotech firm notched its 20th bullish rating Thursday to further neutralize a lone Hold. The Rating Credit Suisse analysts ...", "url": "https://finance.yahoo.com/news/credit-suisse-joins-consensus-prescribe-184754262.html", "urlToImage": null, "publishedAt": "2018-09-06T18:47:54Z", "content": "The Street has a lot of faith in Sarepta Therapeutics, Inc. (NASDAQ: SRPT ). The biotech firm notched its 20th bullish rating Thursday to further neutralize a lone Hold. The Rating Credit Suisse analysts Martin Auster, Mark Connolly and Tiago Fauth initiated \u2026 [+1778 chars]"}, {"source": {"id": null, "name": "Cfo.com"}, "author": "Matthew Heller", "title": "Lilly\u2019s Elanco Expects IPO to Raise $1.4B", "description": "The animal health spinoff is the second major industry player to go public, following Zoetis' successful offering.", "url": "http://ww2.cfo.com/ipos/2018/09/lillys-elanco-expects-ipo-to-raise-1-4-billion/", "urlToImage": null, "publishedAt": "2018-09-06T18:25:38Z", "content": "The spin-off of Eli Lilly\u2019s Elanco business expects to raise $1.4 billion from an initial public offering as it seeks to cash in on the growing market for animal health business. Elanco Animal Health said in an amended prospectus filed Wednesday that it is of\u2026 [+1874 chars]"}, {"source": {"id": null, "name": "Ip-watch.org"}, "author": "David Branigan", "title": "Students, Activists, Swarm To Demand UCLA Drop Indian High Court Patent Claim", "description": "Thousands of students have urged a major research university in the United States to drop a patent claim in India related to an important cancer medicine, with the aim of making affordable versions available.", "url": "http://www.ip-watch.org/2018/09/06/students-activists-swarm-demand-ucla-drop-indian-high-court-patent-claim/", "urlToImage": "http://media.ip-watch.org/weblog/wp-content/uploads/2018/09/ucla-bear.jpg?6e9db4", "publishedAt": "2018-09-06T13:42:59Z", "content": "Thousands of students have urged a major research university in the United States to drop a patent claim in India related to an important cancer medicine, with the aim of making affordable versions available. UCLA campus mascot is rather unwelcoming Universit\u2026 [+2040 chars]"}, {"source": {"id": null, "name": "Business-standard.com"}, "author": "SI Reporter", "title": "Sun Pharma, Glenmark Pharma, Hikal hit 52-week highs; Aurobindo surges 8%", "description": "Granules India, Hikal, Pfizer, Lincoln Pharmaceuticals, Astrazeneca Pharma India and Aarti Drugs were up between 4% and 7%.", "url": "https://www.business-standard.com/article/markets/sun-pharma-glenmark-pharma-hikal-hit-52-week-highs-aurobindo-surges-8-118090600637_1.html", "urlToImage": "https://bsmedia.business-standard.com/_media/bs/img/article/2017-09/14/full/1505408215-9118.jpg", "publishedAt": "2018-09-06T09:35:00Z", "content": "Shares of pharmaceutical companies were back in focus with Sun Pharmaceutical Industries and Glenmark Pharmaceuticals hitting their respective 52-week highs on the National Stock Exchange (NSE). Aurobindo Pharma has rallied 8%, while Biocon, Divi\u2019s Laboratori\u2026 [+3036 chars]"}, {"source": {"id": null, "name": "Fiercepharma.com"}, "author": "Eric Sagonowsky", "title": "Amid EpiPen shortage, Kal\u00e9o strikes Walgreens pact to stock competitor nationwide", "description": "Mylan's EpiPen supply issues have been well documented, and now a competitor seeks to steal market share through a new deal with Walgreens.", "url": "https://www.fiercepharma.com/pharma/amid-epipen-shortage-kaleo-strikes-walgreens-pact-to-stock-competitor-nationwide?utm_source=internal&utm_medium=rss", "urlToImage": "https://qtxasset.com/fiercepharma/1536246682/WalgreensStore.jpg/WalgreensStore.jpg?Q.sitmsGQQVhrBwJRZly3rPSjzOkPpVZ", "publishedAt": "2018-09-06T15:11:51Z", "content": "Amid a national shortage for Mylan\u2019s EpiPen\u2014and during a busy back-to-school season\u2014competitors are making moves aimed at stealing share. After a recent Novartis deal to scoop up rights to Symjepi from Adamis, Kal\u00e9o Pharma has become the latest drugmaker to s\u2026 [+2512 chars]"}, {"source": {"id": null, "name": "Agiledrop.com"}, "author": null, "title": "Agiledrop.com Blog: AGILEDROP: Digital Transformation and Enterprise sessions you don't want to miss at Drupal Europe", "description": "There will be a lot of sessions at DrupalEurope. So many, in fact, you can\u2019t attend all you would want to. Therefore, we have made a short list of the Digital Transformation and Enterprise sessions you don't want to miss. We sure won't. Avoiding the \"best pra\u2026", "url": "https://www.agiledrop.com/blog/digital-transformation-and-enterprise-sessions-you-dont-want-miss-drupal-europe", "urlToImage": null, "publishedAt": "2018-09-06T23:31:21Z", "content": "There will be a lot of sessions at DrupalEurope. So many, in fact, you can\u2019t attend all you would want to. Therefore, we have made a short list of the Digital Transformation and Enterprise sessions you don't want to miss. We sure won't. Thursday, September 13\u2026 [+3326 chars]"}, {"source": {"id": "reuters", "name": "Reuters"}, "author": "Reuters Editorial", "title": "Walgreens to supply Kaleo's allergy shots as EpiPen shortage drags", "description": "U.S. drugstore chain Walgreens Boots Alliance Inc said on Thursday emergency allergy shots from Kaleo will be available in its stores, the latest effort to address shortages of the lifesaving treatment during the back-to-school season.", "url": "https://www.reuters.com/article/us-walgreens-boots-kaleo/walgreens-to-supply-kaleos-allergy-shots-as-epipen-shortage-drags-idUSKCN1LM1O4", "urlToImage": "https://s4.reutersmedia.net/resources/r/?m=02&d=20180906&t=2&i=1301453987&w=1200&r=LYNXNPEE8514V", "publishedAt": "2018-09-06T12:02:01Z", "content": "(Reuters) - U.S. drugstore chain Walgreens Boots Alliance Inc said on Thursday emergency allergy shots from Kaleo will be available in its stores, the latest effort to address shortages of the lifesaving treatment during the back-to-school season. There has b\u2026 [+745 chars]"}, {"source": {"id": "reuters", "name": "Reuters"}, "author": "Reuters Editorial", "title": "Lilly's Elanco unit expects IPO to raise up to $1.45 bln", "description": "Eli Lilly & Co's Elanco Animal Health unit on Thursday said it expects its initial public offering of 62.9 million shares to raise up to $1.45 billion.", "url": "https://www.reuters.com/article/us-elanco-animal-health-ipo/lillys-elanco-unit-expects-ipo-to-raise-up-to-1-45-billion-idUSKCN1LM1H8", "urlToImage": "https://s2.reutersmedia.net/resources/r/?m=02&d=20180906&t=2&i=1301435895&w=1200&r=LYNXNPEE850ZD", "publishedAt": "2018-09-06T11:02:01Z", "content": "(Reuters) - Eli Lilly &amp; Co\u2019s Elanco Animal Health unit on Thursday said it expects its initial public offering of 62.9 million shares to raise up to $1.45 billion. The IPO is expected to be priced between $20-$23 per share. At the high end of the range, t\u2026 [+614 chars]"}, {"source": {"id": null, "name": "Xconomy.com"}, "author": "Frank Vinluan", "title": "SpringWorks Therapeutics Promotes Saqib Islam to CEO", "description": "<p>Saqib Islam has been appointed CEO of SpringWorks Therapeutics. He will also join the New York company\u2019s board of directors. Islam was previously chief financial and chief business officer of SpringWorks. Islam came to SpringWorks last year from Cambridge,\u2026", "url": "https://www.xconomy.com/new-york/2018/09/06/springworks-therapeutics-promotes-saqib-islam-to-ceo/", "urlToImage": null, "publishedAt": "2018-09-06T21:26:50Z", "content": null}]}